The Impact of Advancements in Biotechnology on the Treatment of Disease & Aging

Biotechnology report cover

A new PreScouter report investigates how new innovations and billions of dollars in research can improve the health and longevity of patients

While advances in biotechnology open up the treatment and even the cure of chronic disease, one of the current barriers facing biotechnology moving forward is purely logistical.”

— Dr. Vidhya Sivakumaran, PreScouter

CHICAGO, ILLINOIS, USA, April 23, 2019 / — PreScouter, a Chicago-based research intelligence company, has released a detailed report on the recent advances in biotechnology and how these advances are helping promote better treatments of disease and slow down the aging process. With the biotechnology sector expected to reach nearly 727 billion USD by 2025 and with the enormous number of advances in the field every month, PreScouter identifies in this report which innovations are particularly likely to have an impact in the next 5 to 10 years and what groups are powering these discoveries.

Dr. Vidhya Sivakumaran, the author of the report, notes that while advances in biotechnology open up the treatment and even the cure of chronic disease, “one of the current barriers facing biotechnology moving forward is purely logistical; a number of steps in the research process face logistical hurdles which have yet to be overcome by the development of novel processes.” By providing both a scientific and business perspective on the industry, this report highlights what these logistic barriers are and how they may be overcome by the cutting-edge research happening today.

The report first highlights advances in cell therapies and gene editing and their potential in slowing down the aging process and curing disease. The second part addresses the challenges faced in curing diseases and advancing health, exploring areas such as the microbiome, nano-scale therapies, and personalized medicine. The report includes an exclusive interview with Dr. Trevor Martin, CEO of Mammoth Biosciences, a biotechnology company specializing in developing CRISPR-based diagnostic tools. According to Dr. Martin, he sees “CRISPR systems becoming the platform for a wide variety of applications beyond gene editing over the next 5-10 years.”

“Biotechnology may lead to the creation of new tissue for transplantation, cell, and gene therapies which may lead to cures for chronic diseases and even a treatment for aging,” notes Dr. Sivakumaran. However, improvements in the underlying science are required to power these discoveries, adds Sivakumaran. PreScouter presents this report to serve as a robust primer, highlighting potentially disruptive advances in the field of biotechnology. The report comes as the first chapter of a series of “disruptors” reports PreScouter will be releasing successively.

About PreScouter, Inc.: PreScouter provides research support services to help business leaders make better R&D, product development, and corporate development decisions. PreScouter’s custom-selected teams of Advanced Degree Researchers and Industrial Experts connect business leaders with new markets, commercializable technologies, industry-impacting startups, and other actionable data. PreScouter’s growing list of 500+ clients includes GE Healthcare, Coca-Cola, BAE Systems, Clorox, and Volvo. For more info, please visit

Mariam Jomha
+1 872-222-9225
email us here

Source: EIN Presswire

Immunitor initiates Phase II trial of oral immunotherapy vaccine to treat glioblastoma brain cancer

We currently have off-the-shelf version of allogeneic vaccine, but at the same time we are capable of making individualized, autologous vaccine in as short as one-week time”

— Aldar Bourinbaiar

HONG KONG, HONG KONG, April 23, 2019 / — Immunitor China Ltd. (Hong Kong) announces launching immunotherapeutic V-Boost vaccine trial in patients with most common form of brain tumor – glioblastoma multiforme (GBM). The open-label Phase II trial (NCT03916757), which is now recruiting, is expected to enroll at least 20 patients with newly diagnosed or recurrent glioblastoma who may have undergone surgical removal of their tumor.

Glioblastoma multiforme (GBM) is a high-grade glioma and the deadliest astrocytic tumor, composed of variously differentiated neoplastic astrocytes – a subtype of brain cells forming the central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. In recent years, glioblastoma became more familiar to the public due to extensively-publicized association with names of senators Ted Kennedy and John McCain, and Joe Biden’s son Beau. The estimated 15,000 people in the USA are diagnosed with glioblastoma annually and have a median survival of 12 to 15 months; less than 5% are alive after five years. Almost every patient with this malignant cancer faces poor survival odds since yearly death rate is the same as the annual incidence.

Finding an effective, but at the same time non-toxic treatment, for brain tumors has been a major challenge. The FDA approved drugs temozolomide, bevacizumab, dinutuximab, lomustine and carmustine wafers have shown modest improvements in progression-free or overall survival, but insignificant percentage of complete remissions. The dozens of drug candidates evaluated in the past decade have failed to improve survival beyond the standard of care. Various immunotherapies and cancer vaccines tested in last few years made no meaningful progress, although research is underway with hope of finding cure.

Immunitor’s V-Boost is a stable-at-room-temperature cancer vaccine derived from a pool of patients’ own cancer cells circulating in their blood and samples of tumor tissues, which are hydrolyzed and formulated into proprietary oral tablet to be taken once-daily. Tumor antigens are delivered via antigen-presenting cells lining the gut – the largest immune organ in a human body that can play a role like that of dendritic cells. Prior studies have shown V-Boost educated immune cells can pass blood-brain barrier and found to be effective and free of harmful inflammation. It is believed that V-Boost performs better than vaccines based on dendritic cells as these represent only a minor fraction of cells involved in immune regulation.

Over the course of the Phase II trial, participants will receive daily pill of V-Boost in addition to standard of care, which may include surgery, chemotherapy, radiation, or checkpoint inhibitors. The trial’s main goal is to evaluate effect on tumor shrinking and assess overall or progression-free survival as secondary endpoints. “The response we see in some patients with brain disorders is very encouraging, it is not limited to GBM only, which equals to global market size USD 1.15 billion by 2024 – representing the tiny proportion of CNS therapeutics worth $128.9 billion”, says Dr Allen Bain, the Director of Vancouver-based Immunitor Inc. “We look forward to outcome of Phase II trial to confirm our preliminary findings. The potential will be substantial since brain cancers are in unmet need category”, said Dr. Aldar Bourinbaiar – CEO of Immunitor holding company. “Our V-Boost vaccine has been clinically validated starting some years ago; given familiarity with excellent safety and efficacy of this product in patients with neurodegenerative diseases it will facilitate our effort of seeking approval for tumor cancers. We currently have off-the-shelf version of allogeneic vaccine, but at the same time we are capable of making individualized, autologous vaccine in as short as one-week time”, added Dr. Bourinbaiar.

About Immunitor
Immunitor is a commercial stage biopharmaceutical company registered in Hong Kong with subsidiaries in Beijing, Ulaanbaatar, Moscow, Johannesburg, and Vancouver. Immunitor’s strength and leading position resides in its affordable oral vaccine’s platform validated by multiple clinical trials conducted over last two decades. Immunitor markets 22 oral immunotherapy products addressing major health problems, i.e., in infectious diseases area; a variety of autoimmune and metabolic diseases; and recently in immuno-oncology space. Immunitor has successfully launched advanced trials for hepatocellular carcinoma, cholangiocarcinoma, and pancreatic cancer. Last year, Immunitor started five Phase 2 trials in patients with endometriosis, uterine fibroids, cervical, ovarian, and breast cancer. These and additional immunotherapy studies for other indications are still ongoing.

Aldar Bourinbaiar
Immunitor Inc
+1 301-476-0930
email us here

Source: EIN Presswire

VAFFLE APP Releases News that Almost Half of the Hospitals in the UK will Permit Outdoor Vaping

Vaping Zone

VAFFLE APP Releases News that More UK Hospitals will Permit Outdoor Vaping

Quit Smoking

The hospitals have removed smoking shelters and replaced them with designated outdoor vaping points

Almost half of the hospitals in the UK reported a change in their vaping policies as guidance from PHE suggests vaping on hospital grounds should be lifted.

Cigarette smoking is still a major cause of ill health and death in the UK, related policies need to be updated according to the latest scientific evidence.”

— Vaffle

NEW YORK, UNITED STATES, April 23, 2019 / — Almost half of the hospitals in the UK reported a change in their policies towards vaping. This move is a result of the recommendation by Guidance from Public Health England (PHE). They suggested that vaping on hospital grounds should be lifted.

One of the most recent hospitals to follow these recommendations is NHS Tayside in Scotland. Vaping is now allowed on the grounds of the hospital. However, vapers should still avoid entrances, doorways and seating areas to make sure those surrounding are not exposed to nicotine vaper.

Tayside is the third Scottish hospital to allow the use of e-cigarettes on its grounds after NHS Scotland lifted the e-cig ban. Recently, a Nottingham hospital chose to allow the use of e-cigs their grounds, too.

“We are pleased to be able to update our smoking policy and take into account the latest scientific evidence,” said Andrew Radley, a consultant for the public health pharmacy.

“NHS Tayside is a health-promoting organization and encourages all of our patients, visitors and staff to observe our smoking policy and keep all of our premises and grounds smoke-free.”

Officials now want vaping allowed inside and outside of hospitals too.

The hospitals have removed smoking shelters and replaced them with designated outdoor vaping points. New signage has been installed across the sites, particularly in areas where smokers used to gather as well.

Officials went one step forward and now want vaping allowed inside and outside hospitals.

The Tobacco Control Plan continued with the statement that vaping products should also be sold in hospital shops. This plan even considers allowing vaping in hospital beds when the patient is in a single room.

The decision was made following widespread evidence that e-cigs help people reduce their intake, and are significantly less harmful than regular cigarettes. And besides that, according to the latest study published in the New England Journal of Medicine, cigarettes are almost twice as effective as nicotine-replacement therapy (NRT) to help individuals quit smoking when both are accompanied by behavioural support. It shows that switching to an e-cigarette could be one of the most effective ways to quit smoking.

However, ‘A Freedom of Information’ request has shown that over half of the hospitals in the UK have an outright ban on vaping. 170 NHS trusts responded, 55% of which explained that they banned vaping both indoors and outdoors. 89% of respondents banned vaping inside the hospital.

+86 137 9524 8180
email us here
Visit us on social media:

Source: EIN Presswire


Authentico Technologies

Swedish company changes the playing field for storing passwords and encryption keys.

Authentico Technologies (PC:Private company)

GOTHENBURG, SWEDEN, April 23, 2019 / — The Swedish based cybersecurity start-up Authentico Technologies, developed a centralized hardware unit that can be installed on an enterprise’s servers. The product, named CIPHRA, is a hardware device that makes password theft essentially impossible even if a database is stolen. Passwords and other sensitive data are protected because no secret key material are stored anywhere. The device works as a plug-and-play product and, once running, it enhances security without any change in the user experience or login process.

The technology called PUF (physically unclonable functions) is used by turning this slightly noisy fingerprint of the chip into a reliable root key. Whenever the root key is needed by the system, CIPHRA reliably reconstructs it without the need for storing this root key in any form of memory and They are virtually impossible to clone or predict.

When using PUF, cryptographic keys and identities are derived from a digital fingerprint in the start-up behavior of SRAM cells. This means the secret material is never stored in memory and no physical traces can be found on a chip that lead to the secret material. Hence, using SRAM PUF protects secrets from reverse engineering attacks, simply by virtue of the fact the secrets are not present on the chip in any physical form. So, besides removing the requirement for externally provisioning keys to chip (because they are created from the silicon imperfections internally), storing keys with PUF also provides a level of se¬curity that cannot be achieved with any other form of key storage, due to the fact that keys are not physically stored on the chip.

“Our approach, to generate strong unclonable keys and not store them anywhere, makes theft of passwords and encryption keys essentially impossible,” said Philip Lundin Weinstock, chief executive officer of Authentico Technologies. “The exposure of passwords has reached alarming levels, there are approximately 8 billion stolen passwords that are accessible via the dark web today and new data breaches are reported more or less each month now”.

We guarantee our customers that passwords, or the password hashes are useless to an attacker if they get stolen, regardless of the password strength and the resources available to the hacker. This is something that can not be guaranteed by recommended hashing algorithms since the time it takes to crack a password offline, depends on the strength of the password itself. Weaker passwords get cracked very fast using sophisticated dictionary lists and brute force attacks with dedicated hardware. Besides that these kind of attacks improves all the time, hardware is also getting cheaper and more powerful every single year.

The major problem with the current approaches is that they do not stop data from being stolen in the first place. Rather it might delay the use of the stolen data for an uncertain period of time that depends on both the computational resources available to the attacker and weaknesses being found in algorithms, along with findings published by researchers.
One of the key problems is that personally identifiable infor¬mation is stored using industry standard architecture which is vulnerable to various attacks. Encryption keys can usually be exploited inside code or maintained in files on servers and wherever they are stored. Hackers and insiders can in¬filtrate those hidden places which put the whole organiza¬tion at serious risk.

Philip says: “The problem we see is that the vast majority of users do not change their behavior – How many years have the community informed people about generating strong passwords, turn on two factor authentication and use a recommended password manager?
A tiny minority does that, but the majority does not. We must ask ourselves, what can we do to improve the security for the users, not what the users can do themselves”.

Philip Lundin Weinstock
Authentico Technologies
+46 73 322 10 40
email us here
Visit us on social media:

Source: EIN Presswire

Tissue Solutions Ltd wins Queen’s Award for Enterprise….Again

Tissue Solutions

Tissue Solutions Ltd, an award winning tissue acquisition company has won the prestigious Queen's Award for Enterprise in the International Trade category.

GLASGOW, UNITED KINGDOM, April 23, 2019 / — Tissue Solutions Ltd, an award winning virtual biobank and tissue acquisition company that helps researchers ethically source biological materials, has won the prestigious Queen's Award for Enterprise in the International Trade category. Now in its 53rd year, these awards are announced on the Queen’s birthday and are one of the UK’s highest accolades recognising business achievement. It is the second time Tissue Solutions has been recognised for its excellence in International Trade, having also collected the award in 2014.

Commanded by CEO Dr Morag McFarlane, the company has been supplying high quality human biomaterials and scientific expertise to multinational companies since 2007. It is now an established and reputable supplier of biospecimens, and the only UK-owned human tissue acquisition group. Sourcing through a global network, the company provides scientists with biomaterials for pre-clinical research across the drug development pipeline, from identification and validation, screening and testing, right through to pre-clinical trials. Samples can be anything from fresh tumour samples, used for work on Immuno-Oncology, to skin samples for use in toxicology and dermatological testing of products. They specialise in supplying samples to stringent specifications, offering exceptional turn-around times and taking care of the logistics of transporting biomaterials across geographical borders. Samples can also be collected on demand, through the companies volunteer donor database, where volunteers can sign up to donate samples to support research in areas close to their heart.

The award has been presented in recognition of Tissue Solutions’ outstanding business success within International Markets and achieved by continual investment in growth and innovation. In the last three years, Tissue Solutions has seen overseas growth of 216 per cent and over 80 per cent repeat order success by servicing global clients across Europe, USA, Australia and Asia. The business currently employs 20 staff and is based at the West of Scotland Science Park in Glasgow.

Dr Morag McFarlane CEO of Tissue Solutions said, “We are thrilled to receive the Queen’s Award again for Enterprise in the International Trade category. Our foundations were built on the development of a sample acquisition service, and we now also offer a comprehensive range of tissue related CRO services as standard, as well as a range of bespoke services”

Morag said: "The award is an acknowledgment of the effort put in by everyone at Tissue Solutions to ensure the best possible customer service to our clients, who have shown their appreciation by their custom and loyalty. Our philosophy is that the best research comes from the best samples, and we are proud to be supporting advancements in biomedical research"

For further information on Tissue Solutions visit
Tissue Solutions Ltd
+44 141 299 0055
email us here
Visit us on social media:

Source: EIN Presswire

Onchain Custodian, the crypto & digital asset custodian backed by Sequoia, announces its first customers & partnerships

Onchain Custodian clients and partners 23/04/2019

First batch of clients & partners

Onchain Custodian

Onchain Custodian Executives

Onchain Custodian, the digital asset custodian backed by Sequoia, Fosun & DHVC, announced today the on-boarding of its first customers & important partnerships.

SINGAPORE, April 23, 2019 / — Following its successful platform and service launch, Onchain Custodian (ONC), the digital asset custodian backed by Sequoia, Fosun and DHVC, announces today the on-boarding of its first customers as well as the establishment of important partnerships.

Headquartered in Singapore, Onchain Custodian has developed a personalized and comprehensive custody service for institutional players and accredited investors to secure digital assets with institutional grade security and controls. The SAFE™ Digital Asset Custody Platform is flexibly built to meet the possible futures of digital asset custody.

Onchain Custodian’s launch event took place at the Mandarin Oriental Singapore on the 11th of April during the Asia Pacific Blockchain New Finance Summit. The event attracted VIP guests from all over the world, from Canada to China. Some have announced at this occasion their plans to use Onchain Custodian’s services.

On top of the Ontology Foundation, which announced publicly two weeks ago its use of the service, Tembusu Partners, Pre Angel, JLAB | JD Capital, Fission Capital, Frees Fund, Timestamp Capital, Milestone, among seven others, will start the on-boarding process with Onchain Custodian in the coming weeks.

Mr. Pak Lum MOCK, Managing Partner at Tembusu Partners. “As a leading private equity firm with deep roots in Emerging Asia, Tembusu holds digital asset investments that we want to be safe and properly managed. We trust that Onchain Custodian, with its strong Asia Pacific footprint, will offer us the personalised service we are looking for.”

Mr Jian SUN, Founder of JLAB | JD Capital: “Onchain Custodian’s founders and backers are a strong testimonial of the seriousness of the project. By safekeeping our digital assets with ONC, we are following the best practice that should prevail for any institutional investments; independent third-party custody.”

Ms Sandy Peng, Partner of Fission Capital: “Digital asset investments are tricky to manage in view of the current diversity of blockchain and token protocols. Having the secure single window access to blockchains that Onchain Custodian offers will help us manage our investments”.

During its launch event, Onchain Custodian also announced important partnerships with channel partners such as Infinito who will help promote ONC’s services, but also industry groups. Alexandre Kech, CEO ONC: “Best practices around digital asset custody are critical to the future of this industry. We are committed to work with customers but also associations like the Distributed Regtech Collaboration Platform, the Malaysia Blockchain Association or the Digital Exchange Association to build the global standard for digital asset custody.”

Additional partnerships includes Accuity, the renowned compliance platform provider that ONC will use for its KYC and AML/CFT compliance process, and Polymath, a globally known Securities Token platform which will refer Onchain Custodian as one of its custodian service providers.

Thomas Borrel, Polymath: "Reputable custodians are a critical component in the security token issuance journey, especially as institutions look for new and innovative way to generate growth. We are thrilled to partner with Onchain Custodian to provide our Asia-based Issuers with a secure and dependable custody solution."

Onchain Custodian Team
Onchain Custodian
+65 6909 9350
email us here
Visit us on social media:

Expect the unexpected…

Source: EIN Presswire

Gabriel Patterson, Winnipeg Personal Trainer, is Pleased to Announce New Meal Planning and Nutrition Coaching Services

To further his practice, Gabriel Patterson now adding meal planning and nutrition coaching for his clients.

TORONTO, CANADA , April 22, 2019 / — Gabriel Patterson’s mission to assist his clients in their fitness goals is now going beyond the physical exercise portion of a healthy lifestyle. According to Mr. Patterson in a recent interview, “I am launching a meal planner and nutrition coaching that will provide personalized recipes daily, menus and grocery lists, and will personalize all recommendations for their objectives – such as athletic performance, weight loss, cleansing, etc.” Mr. Patterson has the understanding that a balanced lifestyle is lopsided without a focus on nutrition, and is now working to implement services that will help with this aspect of healthy living.

Clients will soon be able to receive more customized assistance from Winnipeg native, Mr. Patterson when it comes to the fuel they consume. A meal planning service can help with the day to day menus to help simplify their nutrition needs to keep up with their busy schedules. Nutrition coaching services can assist clients in making the best decisions possible when it comes to what they eat.

A fitness trainer living in Toronto, Gabriel Patterson seeks a deeper connection with his clients, focusing on many cases of sports-related injuries. Making a point to learn more about his clients individually, he can better help them in determining and reaching their health goals. His training philosophy combines a balanced lifestyle and diet that’s enriched using meditation and mindfulness. Mr. Patterson can be found enjoying the culture that Toronto has to offer and practicing what he preaches when not at work, as he can normally be spotted at a yoga class, going cycling, or being with his friends and family.

Contact Gabriel Patterson today to learn more about his exciting new services helping clients with their healthy diet goals.

Gabriel Patterson
Patterson Training
+1 416-371-1768
email us here

Source: EIN Presswire

Lakeland, Florida Doctor Selected to the "America's Best Physicians" 2019 Directory

Dr. Hana J. Clements

Dr. Hana J. Clements

Dr. Hana J. Clements, MD Listed as Top Doctor in Internal Medicine

Dr. Hana Clements Selected as Best in Internal Medicine”


LAKELAND, FLORIDA, UNITED STATES, April 22, 2019 / — Lakeland, Florida doctor, Dr. Hana J. Clements, MD has been selected to the "America's Best Physicians" registry for 2019. Selections were made by the National Consumer Advisory Board, an organization that identifies top professionals in their fields.

Dr. Clements practices Internal Medicine at 1629 Lakeland Hills Blvd. in Lakeland serving patients throughout Central Florida.

Services include: General Internal Medicine, Addiction Medicine, Transgender Medicine and Weight Loss Therapy.

Dr. Clements received her Medical Degree (M.D.) from Masaryk University Medical School. She completed her residency in Internal Medicine and Pediatrics at Bridgeport Hospital in Affiliation with the Yale University School of Medicine (1994-1998).

In addition to the large scope of Internal Medicine, Dr. Clements also specializes in treating patients with Opioid and other Drug Dependencies, Hormonal Therapy for Transgender patients, and Medical Management for Diet and Weight Control. Dr. Clements is a member of Central Florida Physicians Alliance. She is Board Certified by American Board of Internal Medicine.

For more information, please go to or contact Dr. Hana J. Clements, MD directly at 863-687-9333

The "National Consumer Advisory Board" accepts no fees, sponsorships, donations or advertising in their selection process. Doctors were chosen following an application based on training, experience, continuing education, and dedication to excellence. Only Doctors that satisfy all of the board's criteria can qualify for inclusion in the "Americas Best Physicians" directory.
Americas Best Physicians
+1 475-282-3043
email us here

Source: EIN Presswire

Cascade Environmental Releases Latest Corporate Sustainability Report

2018 CSR Cover press release

Cascade is taking its reporting efforts to the next level with its 2018 CSR

We are taking our reporting efforts to the next level with this, our fifth annual report”

— Sue Bruning, Sustainability Council Chair

BOTHELL, WASHINGTON, UNITED STATES, April 22, 2019 / — Cascade Environmental (“Cascade”), a leading field services contractor of drilling, site investigation, and remediation services celebrates Earth Day with the release of its 2018 Corporate Sustainability Report.

“We are taking our reporting efforts to the next level with this, our fifth annual report,” explains Sue Bruning, Chair of Cascade’s Sustainability Council. “This report covers the calendar year 2018 and, in many places, we’ve included data from our two previous reports to help our stakeholders understand the trends in our business and our progress towards stated goals. The data provided in the report represents the entire Cascade family of brands and has been prepared in accordance with the GRI Standards: Core option,” says Bruning.

The topics and data provided in this report were thoughtfully identified through extensive engagement efforts and material assessments. Highlights of the report include:

• World-class behavior-based safety program that has institutionalized hazard identification and risk mitigation throughout the organization, leading to an unprecedented OSHA Total Recordable Injury Rate of 0.58 for environmental field services industry.

• Sustainable sourcing practices to optimize business with preferred suppliers and promote strategic relationships with local vendors, including new vendor screening and 30% increase in spending with certified diversity-owned businesses

• Increased fleet fuel efficiency through the implementation of electronic logging devices, updating over-the-road and off-road assets, and utilization of electric drill rigs

• Launch of Cascade Diverse Workforce Initiative to tackle diversity and inclusion challenges for ethnic minorities, women, and veterans in the traditionally male-dominated field services industry

Cascade’s 2018 Annual Sustainability Report is available on the company’s website at

About Cascade:
Cascade is a field services contractor that partners with our clients to provide seamless environmental and geotechnical solutions from concept to completion. Our vision is to integrate technology, safety, sustainability and human potential to tackle the challenging environmental and geotechnical issues facing our clients. For more information on Cascade, please visit

Sue Bruning
Cascade Environmental
+1 567-202-3525
email us here
Visit us on social media:

Source: EIN Presswire

Understanding allergies in Children, explained by Pediatrician Dr. Kenneth Rebong

Pediatrician Dr Kenneth Rebong, San Jose California

Pediatrician Dr Kenneth Rebong, San Jose, California

Office of Dr Kenneth Rebong, San Jose, CA

Office of Dr Kenneth Rebong, San Jose, CA

Dr Kenneth Rebong Profile on Hippocratesguild

Dr Kenneth Rebong Profile on Hippocratesguild

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong Profile on MedicoGazette

Dr Kenneth Rebong Profile on MedicoGazette

About 1 in 4 children in the U.S. suffer from allergies. Allergies can develop at any age, but the causes are still being explored. Dr. Kenneth Rebong explains.

Kenneth Pomar Rebong, MD (N/A:N/A)

More recently, a large international scientific study found five genetic indicators that are related to food allergies. Thus, apparently there are genetic risk factors for allergies.”

— Dr. Kenneth P Rebong, pediatrician

SAN JOSE, CALIFORNIA, UNITED STATES, April 22, 2019 / — In brief, an allergy is an overreaction of the immune system to something (called “allergen”) that does not affect other people. When a person has allergies, the body attacks these allergens with reactions that range from mild to potentially fatal. In children, allergies often include sensitivities to certain foods (such as peanuts or eggs), medications, or environmental factors (such as pollen or animals).

Medical doctor Kenneth P. Rebong, MD has published an informational article for parents to better understand allergies. The complete article will be published on the Blog of Dr. Kenneth Rebong at

Dr. Rebong explains what we know about allergies. When your body experiences something new such as a specific airborne particle, it mistakes the foreign substance as harmful. The body then produces immunoglobulin E, which are antibodies that attach to certain cells, which release a chemical known as histamine upon contact. This chemical causes inflammation and is the cause behind the allergic symptoms.

Allergy Symptoms

Allergies have a wide range of symptoms. Some sneeze constantly, some develop watery eyes, choking and others experience swelling on the face. Following are a few common symptoms of allergies:
* Hives
* Tingling in mouth
* Stomach ache
* Swelling of the tongue, lips, face or throat
* Anaphylaxis
Allergic Reactions from Insect Bites
* Swelling where the insect stung
* Shortness of breath, cough, wheezing or chest tightness
* Itching or hives
Allergic Reactions from Medication
* Itchy skin
* Rashes
* Hives (red spots on the abdomen, chest or back)
* Wheezing
* Facial swelling
Allergic Airborne Reactions from Hay Fever
* Runny, stuffy nose
* Sneezing
* Watery, swollen or red eyes
* Itching of the eyes or nose
* Coughing

Initially, parents may think that their child has a cold, and not allergies. At first glance, the symptoms are similar, such as a runny nose, watery eyes, congestion and sneezing. However, colds usually wane after about 10 days, but allergies do not. Thus, if symptoms persist, you should take your child to see a pediatrician. Allergies are quite common. It is estimated that 1 in 4 children have some allergy. If your child is affected, you want to know more about allergies.

Where do Allergies come from?

Scientists and researchers have yet to discover what exactly causes allergies, but there are some theories and scientific research. One of them is the “Hygiene Hypothesis.” This hypothesis states that when a person tries to force himself into a hygienic environment, the response to bacteria causes the allergies. We need a certain amount of exposure to infections and germs, so that our immune system can build a threshold. When we are extra careful, to the point where we can’t stand to be an environment where there’s a little dust or dirt, the body overreacts to the germs.

According to a study published in the American Journal of Respiratory and Critical Care Medicine, the real reason behind adult allergies is excessive cleaning. The study looked at more than 3,000 participants who didn’t have asthma. These participants used different kinds of cleaning sprays in home. After a week, the participants had a medical checkup and it was revealed that 42% of them were showing signs of asthma.

More recently, a large international scientific study found five genetic indicators (genetic risk loci) that are related to food allergies. Thus, apparently there are genetic risk factors for allergies. See

About Dr. Kenneth P. Rebong

Dr. Kenneth Pomar Rebong, MD, a medical doctor in San Jose, California, and specializes in Pediatrics and Adolescent Medicine. He completed his Pediatric Residency at Rutgers University in New Brunswick, New Jersey.

Kenneth Pomar Rebong, MD
Kenneth Pomar Rebong, MD
+1 408-729-3232
email us here
Visit us on social media:

Allergies in children: causes, symptoms, and treatments explained

Source: EIN Presswire